SCHEMBL30285657

SCHEMBL30285657

CC(=O)N(c1cc(NC(=O)Cc2ccccc2Cl)ccn1)c1ccccc1F

nearest known ligand 0.67

Predicted protein targets (top 7)

geneUniProtsupporting neighboursconfidence
P2RX4 Q99571 6/20 0.67
ANO1 Q5XXA6 11/20 0.52
RORA P35398 1/20 0.48
NR2E1 Q9Y466 1/20 0.48
KCNJ5 P48544 2/20 0.47
KCNJ3 P48549 2/20 0.47
KCNJ6 P48051 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26186542 1.00 P2RX4 (0.67) P2RX4ANO1RORANR2E1KCNJ5
SCHEMBL29005473 0.95 P2RX4 (0.62) P2RX4ANO1RORANR2E1KCNJ5
SCHEMBL30285719 0.93 P2RX4 (0.64) P2RX4ANO1RORANR2E1KCNJ5
SCHEMBL26186543 0.93 P2RX4 (0.64) P2RX4ANO1RORANR2E1KCNJ5
SCHEMBL25370426 0.92 P2RX4 (0.62) P2RX4ANO1
SCHEMBL25371065 0.92 P2RX4 (0.69) P2RX4ANO1RORANR2E1KCNJ5
SCHEMBL26186547 0.92 P2RX4 (0.64) P2RX4ANO1RORANR2E1KCNJ5
SCHEMBL25374746 0.91 P2RX4 (0.68) P2RX4ANO1
SCHEMBL25371053 0.90 P2RX4 (0.81) P2RX4ANO1
SCHEMBL29005443 0.90 P2RX4 (0.62) P2RX4ANO1RORANR2E1KCNJ5

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-115996911-A Substituted N-phenylacetamides having P2X4 receptor antagonistic activity 拜耳公司 2023-04-21 CN claimed
CN-115989218-A Use of N-phenylacetamides having P2X4 receptor antagonistic activity for the treatment of certain eye diseases 拜耳公司 2023-04-18 CN claimed
CN-115996911-A Substituted N-phenylacetamides having P2X4 receptor antagonistic activity 拜耳公司 2023-04-21 CN disclosed
CN-115989218-A Use of N-phenylacetamides having P2X4 receptor antagonistic activity for the treatment of certain eye diseases 拜耳公司 2023-04-18 CN disclosed